vaccine discovery
effective vaccine
vaccine modalities
protective vaccine
vaccine capable
therapeutic vaccine failure
therapeutic vaccine candidates
human vaccine studies
HIV
European AIDS Vaccine Initiative
risk curve
reduced risk of failure
late stage preventive
late stage development
chance of discovery
novel preventive
human studies
innovative risk prediction methods
competitive research groups
Canadian groups
product development
best immunogens
new infections
effective means
disease progression
global pandemic
years of research
European public institutions
clinical course of disease
novel immunization technologies
small Experimental medicine
lead
vectors
biotechs
boost schedules
EU countries
adjuvants
pool of international expertise
US collaborators
impact of host factors
gender
strategies of viral eradication
selection
highest level
genetics
forces
platform
challenge
Emphasis
people
bottleneck
Animal models
EAVI2020